Biomaterial Database

Botulinum toxin in the treatment of axillary hyperhidrosis. 2003

Ibrahim Galadari, and Jameelah Alkaabi

The Faculty of Medicine and Health Sciences, United Arab Emirates University, Dermatology Department, Al-Ain Hospital, Dubai, UAE. galadari@email.com

BACKGROUND Axillary hyperhidrosis can be a source of social isolation and embarrassment. The available treatments are either ineffective or have intolerable side effects. The search for a simple, long-lasting, and safe treatment has led to the use of botulinum-A toxin injections in those with excessive axillary hyperhidrosis. METHODS Fifteen patients participated in this study. All had a history of axillary hyperhidrosis of 1-6 years duration and were using different types of therapies without any benefit. Each patient was injected intradermally with 125 units of botulinum-A toxin (Dysport, Spenywood Pharmaceutical) in 5-6 points over an elliptical area on each side. Patient follow-up was performed using the iodine-starch test. RESULTS A total of 14 out of the 15 patients had complete anhidrosis 1 week after the injection. This result lasted for periods ranging from 1-6 months. No side effects were encountered. CONCLUSIONS Intradermal injection of botulinum-A toxin seems to be a safe, rapid, and effective method of treatment in axillary hyperhidrosis.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D009465	Neuromuscular Agents	Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.	Skeletal Muscle Relaxants,Neuromuscular Effect,Neuromuscular Effects,Agents, Neuromuscular,Effect, Neuromuscular,Effects, Neuromuscular,Muscle Relaxants, Skeletal,Relaxants, Skeletal Muscle
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006945	Hyperhidrosis	Excessive sweating. In the localized type, the most frequent sites are the palms, soles, axillae, inguinal folds, and the perineal area. Its chief cause is thought to be emotional. Generalized hyperhidrosis may be induced by a hot, humid environment, by fever, or by vigorous exercise.	Hyperidrosis
D000293	Adolescent	A person 13 to 18 years of age.	Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D001365	Axilla	Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.	Armpit,Underarm
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019274	Botulinum Toxins, Type A	A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.	Botulinum Neurotoxin Type A,Botulinum Toxin A,Botulinum Toxin Type A,Botox,Botulinum A Toxin,Botulinum Neurotoxin A,Clostridium Botulinum Toxin Type A,Clostridium botulinum A Toxin,Meditoxin,Neuronox,Oculinum,Onabotulinumtoxin A,OnabotulinumtoxinA,Vistabel,Vistabex,Neurotoxin A, Botulinum,Toxin A, Botulinum,Toxin, Botulinum A